Medtronic reported net sales of $9.81 billion in its fiscal fourth quarter, a 9.9% increase driven by strategic business adjustments. The company also achieved a profit of $1.24 billion, or 96 cents per share, surpassing FactSet’s analyst consensus of $1.54 adjusted earnings per share. Organic sales grew 6.6%, reflecting sustained demand in core markets. This performance marks a significant rebound from prior quarters, where supply chain disruptions and inflationary pressures had constrained growth. Investors are focusing on whether these results signal a turning point for the company’s recovery.

The $9.81 billion revenue milestone comes amid Medtronic’s broader efforts to streamline operations and invest in high-growth areas like diabetes and cardiovascular solutions. The company’s ability to outpace Wall Street’s $9.62 billion forecast highlights improved pricing power and market share gains. However, the 96 cents per share earnings figure, while strong, falls short of some analysts’ optimism, suggesting lingering challenges in scaling new product pipelines. Analysts note that the organic growth rate lags pre-pandemic levels, indicating room for further optimization in cost management and R&D efficiency.

The results underscore Medtronic’s resilience in a sector facing regulatory scrutiny and competition from lower-cost manufacturers. With healthcare spending trends shifting toward chronic disease management, the company’s performance could influence investor confidence in medical-device stocks. While the short-term gains are positive, sustained growth will depend on executing its strategic priorities, including expanding digital health offerings. The $1.24 billion profit provides near-term relief but does not fully address long-term profitability risks from patent expirations and pricing pressures.